Institut de Recherches Internationales Servier

• NCT07235748

  Phase 1, Completed, 28 people, 19 Nov 2025

• Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation

  Phase 1/2, Active, not recruiting, 55 people, 15 Jul 2024

• NCT06225999

  Phase 2, Completed, 41 people, 26 Jan 2024

• NCT04591808

  Phase 3, Terminated, 146 people, 19 Oct 2020

• NCT03672695

  Phase 1, Completed, 37 people, 14 Sept 2018

• NCT03411161

  Phase 1/2, Completed, 22 people, 26 Jan 2018

• NCT02848443

  Phase 1, Completed, 78 people, 28 Jul 2016

• NCT02632708

  Phase 1, Active, not recruiting, 153 people, 17 Dec 2015

Sources: clinicaltrials.gov

• European Commission

  HORIZON-JU-RIA, Collaborative Action and Research for Engagement, Persistence and Adherence in Treatment & Health, 101192133, 2025–2030, 8 May 2025

Sources: cordis.europa.eu